WuXi AppTec opens second NJ-based site following ongoing expansion efforts

By Melissa Fassbender contact

- Last updated on GMT

New Jersey State Senator Linda Greenstein attended the grand opening. (Image: WuXi AppTec)
New Jersey State Senator Linda Greenstein attended the grand opening. (Image: WuXi AppTec)
WuXi AppTec is converting its Plainsboro, NJ lab into a fully GLP-regulated bioanalytics facility after opening a new site in Cranbury which doubles the company’s total operation space to more than 115,000 square feet.

“The company’s strength in bioanalytical and DMPK services has been heavily driven by increasing customer demand for regulatory-compliant solutions over the past two to three years,” ​said Dr. Jason Liu, SVP of WuXi AppTec, COO of the Laboratory Testing Division.

“The site expansion bolsters WuXi’s Laboratory Testing Division in these services and establishes New Jersey site as a center of excellence in providing IND and NDA enabling services,​” he told us.

When fully configured, Liu said the new facility add 55,000 square feet of laboratory space to WuXi AppTec’s Laboratory Testing Division (LTD) as well as more than 200 new jobs.

“This addition expands upon our established Plainsboro facility, offering testing services to pharmaceutical and biotech companies,”​ he explained.

Additionally, “through the expansion efforts,”​ Liu said the company will be converting its current Plainsboro laboratory into a fully good laboratory practice (GLP) regulated bioanalytics facility with double the space.

WuXi’s Laboratory Testing Division provides in vivo​ and in vitro​ assays from early screening to clinical sample analysis, as well as medical device testing from development to product lifecycle management.

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars